Lap-Band gets FDA Warning Letter

Share this article:

An FDA Warning Letter says that oBand Centers in Marina Del Rey, CA, is making misleading claims in its promotional materials for the Lap-Band, a device indicated for weight reduction in certain severely obese adults.

According to the letter, the company's website fails to reveal material facts about Lap-Band risks. The letter also says that a web video that is intended to convey indications for use, contraindications, warnings and adverse events is not accessible to viewers, due to the brief appearance of the information and tiny, blurry print that renders the content illegible.

Earlier in 2012, FDA warned Lap-Band VIP about marketing the Lap-Band gastric banding system in TV spots and billboards that lacked information on the device's use and relevant warnings, precautions, side effects, and contraindications. In 2011, the agency sent five related Warning Letters to weight-loss centers promoting the Lap-Band.

OBand Centers was told to correct the violations and to respond with a list of specific steps taken, documentation of the steps, and a timetable for their completion.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters